The market for diagnostics and treatments for Alzheimer’s disease was estimated at US$ 5,933.5 million in 2021 and is anticipated to grow at a CAGR of 5.6% from 2022 to 2028 to reach US$ 8,603.9 million. Due to the rising disease burden, expanding elderly population, and rising need for innovative diagnostics and therapies, the worldwide market for Alzheimer’s disease diagnostics and therapeutics is expanding rapidly. Additionally, the market for Alzheimer’s disease diagnostics and therapies is anticipated to grow as more attention is paid to the development of innovative diagnostics and medicines and an increase in public knowledge of these topics.
Click Here to Get a Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/5181
Geographically, the worldwide market for diagnostics and treatments for Alzheimer’s disease is divided into North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa.
Due to the rising incidence of Alzheimer’s disease in this area, particularly in the United States, North America is predicted to have the biggest market share over the projection period. For instance, CDC expects that more than 5.8 million Americans will have Alzheimer’s disease by 2020. Beyond the age of 65, the number of individuals living with the disease increases every five years, and by 2060, 14 million people are expected to be affected.
In addition, Asia Pacific is anticipated to have rapid expansion in the worldwide diagnostics and therapies market for Alzheimer’s disease due to rising public awareness and the illness’s rising incidence in this area. For instance, the Alzheimer’s Association (India) reports that more than 60% of dementia sufferers originate from low- and middle-income nations like India. By 2050, this percentage will reach more than 70%.
Over the projection period, it is anticipated that the prevalence of Alzheimer’s disease will rise globally, driving the market for diagnostics and treatments for the condition. For instance, around 55 million individuals worldwide already suffer from dementia, with 10 million new cases are reported year, according to the World Health Organization (WHO). The same source claims that Alzheimer’s disease accounts for 60–70% of dementia cases as well as the most prevalent kind of dementia.
Over the projected period, the global market for Alzheimer’s disease diagnostics and therapies is anticipated to develop as a result of rising need for innovative diagnostic tools caused by an increase in Alzheimer’s disease prevalence worldwide. For instance, C2N Diagnostics has extended its line of Alzheimer’s screening tools after demonstrating that their blood test to gauge the amount of amyloid plaques present in the brain correlates with the outcomes of PET scans in forecasting the onset of Alzheimer’s. The brand-new Research Use Only (RUO) test for Alzheimer’s disease was introduced by C2N Diagnostics in May 2022.
The worldwide market for Alzheimer’s disease diagnostics and therapies is anticipated to present considerable potential prospects due to the rising need for safe and effective Alzheimer’s disease treatments. For instance, Eli Lilly and Company said in June 2021 that donanemab, an experimental antibody therapy for the treatment of Alzheimer’s disease, has been given breakthrough therapy designation by the U.S. Food and Drug Administration (USFDA). Based on the results of the phase 2 trial, the business also plans to file a biologics licence application under an accelerated approval pathway later this year.
For industry participants in the worldwide Alzheimer’s disease diagnostics and therapeutics market, rising public awareness of innovative diagnostics and therapies is anticipated to present attractive growth prospects. For instance, the Alzheimer’s Association began its More Time campaign in March 2021 with the goal of raising awareness of the illness and highlighting the desperate need for a disease-modifying therapy among individuals who are affected by or living with Alzheimer’s. Full-page print ads, digital ads, social media and email marketing, as well as an online town hall meeting, were all part of the campaign. Over 1.1 million people expressed their support for the campaign, and it garnered over 90 million media impressions.
The worldwide market for Alzheimer’s disease diagnostics and treatments is anticipated to expand as a result of an increase in the development of innovative diagnostics and medicines. For instance, the FDA of the United States approved the first in vitro diagnostic to assist in the early diagnosis of Alzheimer’s disease in May 2022. The unique diagnostic reduces radiation exposure hazards for individuals who would normally require positron emission tomography (PET) scans for testing.
The world’s ageing population is anticipated to contribute to the expansion of the market for diagnostics and treatments for Alzheimer’s disease. For instance, when people get older, their chance of having Alzheimer’s disease rises. The number of new and current instances of Alzheimer’s will increase along with the nation’s steadily ageing population. The Alzheimer’s Association estimates that by 2050, there may be 12.7 million individuals aged 65 and older living with Alzheimer’s.
The market for diagnostics and treatments for Alzheimer’s disease is anticipated to expand slowly due to a lack of surrogate indicators and difficulties with early detection. For instance, it has been difficult to get an early diagnosis of Alzheimer’s since the disease’s initial symptoms are typically neglected because they are so mild. As a result, the patient is unable to get any diagnostic or therapeutic care, which may limit the market’s ability to expand.
Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/5181
The worldwide market for Alzheimer’s disease diagnostics and therapies is anticipated to increase slowly due to the high failure rates of late-stage Alzheimer’s medications. With 99% of studies demonstrating no difference between the treatment and a placebo, the failure rate of Alzheimer’s therapy research has remained constant for decades. This amount is particularly significant when you consider the rising number of medicine candidates in the pipeline.
The study on the worldwide market for diagnostics and treatments for Alzheimer’s disease is divided into Product and Region segments.
The market is divided into Therapeutics and Diagnostics based on Product. Due to the increasing incidence of Alzheimer’s disease, both the therapeutics and diagnostics segments are anticipated to dominate the market for diagnostics and treatments for the condition.
Diagnose Alzheimer’s disease or rule out other potential causes of symptoms with the aid of brain scans like computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET).
Therapeutics for Alzheimer’s disease: While there is no known cure, there are medications and non-drug therapies that may slow the disease’s course and improve symptoms.
A final merger agreement between Roche and GenMark Diagnostics Inc. was reached in March 2021 to get access to cutting-edge technology for testing several infections with a single patient sample.
In July 2020, UCB and Genentech, a part of the Roche Group, struck an exclusive licencing agreement for the development and marketing of UCB0107, an avant-garde anti-Tau antibody therapy for Alzheimer’s disease (AD).
A concentration on anaesthetics and speciality products, Aspen Global Incorporated’s Japanese business unit of off-patent branded medications was bought by Sandoz in January 2020.
Key Companies Insights
The market for diagnoses and treatments for Alzheimer’s disease is quite cutthroat. This is explained by the rising global elderly population and the increased demand for safe and efficient tests and medicines.
Some of the major companies in the global market for diagnostics and treatments for Alzheimer’s disease are Pfizer, Luye Pharma Group, Eisai Co. Ltd., Vigil Neuroscience, Biogen Inc., Grifols SA, Johnson & Johnson, Corium International Inc., Eli Lilly & Company, Adamas Pharmaceuticals Inc., Lupin Limited, Abbvie Inc., Apotex Inc., Merz Pharma, Siemens Healthineers AG, and Zydus Cadila.
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/5181
Reasons to buy this Alzheimer’s Disease Diagnostics and Therapeutics Market Report
☑ It attempts an analysis of the competing scenario.
☑ The current and exceptional product revenue market.
☑ An in-depth data on the regional investigation and competitive landscape structure.
☑ It benefits in creating an awareness of the important key product segments.
☑ The marketing strategies, opportunities, and development factors are explained.
☑ Alzheimer’s Disease Diagnostics and Therapeutics market size estimation and recent advancements in the industry are explained.
The Study Objectives are:
✔ A comprehensive insight into key players operating in the Alzheimer’s Disease Diagnostics and Therapeutics Market and their corresponding data.
✔ It includes product portfolio, annual revenue, expenditure on research and development, geographical presence, key developments in recent years, and growth strategies.
✔ Regional analysis, which includes insight into the dominant market and corresponding market share.
✔ It also includes various socio-economic factors affecting the evolution of the market in the region.
✔ The report offers a comprehensive insight into different individuals from value chains such as raw materials suppliers, distributors, and stockholders.
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Alzheimer’s Disease Diagnostics and Therapeutics Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Alzheimer’s Disease Diagnostics and Therapeutics Industry Impact
Chapter 2 Global Alzheimer’s Disease Diagnostics and Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Alzheimer’s Disease Diagnostics and Therapeutics (Volume and Value) by Type
2.3 Global Alzheimer’s Disease Diagnostics and Therapeutics (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Alzheimer’s Disease Diagnostics and Therapeutics Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Alzheimer’s Disease Diagnostics and Therapeutics Market Analysis
Chapter 6 East Asia Alzheimer’s Disease Diagnostics and Therapeutics Market Analysis
Chapter 7 Europe Alzheimer’s Disease Diagnostics and Therapeutics Market Analysis
Chapter 8 South Asia Alzheimer’s Disease Diagnostics and Therapeutics Market Analysis
Chapter 9 Southeast Asia Alzheimer’s Disease Diagnostics and Therapeutics Market Analysis
Chapter 10 Middle East Alzheimer’s Disease Diagnostics and Therapeutics Market Analysis
Chapter 11 Africa Alzheimer’s Disease Diagnostics and Therapeutics Market Analysis
Chapter 12 Oceania Alzheimer’s Disease Diagnostics and Therapeutics Market Analysis
Chapter 13 South America Alzheimer’s Disease Diagnostics and Therapeutics Market Analysis
Chapter 14 Company Profiles and Key Figures in Alzheimer’s Disease Diagnostics and Therapeutics Business
Chapter 15 Global Alzheimer’s Disease Diagnostics and Therapeutics Market Forecast (2022-2028)
Chapter 16 Conclusions
Customization of the Report
Our research analysts will help you to get customized details for your report, which can be modified in terms of a specific region, application or any statistical details. In addition, we are always willing to comply with the study, which triangulated with your own data to make the market research more comprehensive in your perspective.
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027